The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
PEPFAR Implementation: Progress and Promise
TABLE 5-1 PEPFAR Treatment Results by Fiscal Year, 2004–2006
Subcategory
Fiscal Year 2004
Fiscal Year 2005
Fiscal Year 2006
ART
Number of people receiving ART supported by PEPFAR
Number of health workers trained with PEPFAR support in the provision of treatment according to national and/or international standards
12,200
36,500
52,000
Laboratory Infrastructure
Number of laboratories supported by PEPFAR with the capacity to perform (1) HIV tests and (2) CD4 tests and/or lymphocyte tests
Not available
900
958
Number of people trained with PEPFAR support in the provision of laboratory-related services
3,100
5,700
8,300
*Includes both ART and prevention of mother-to-child transmission plus sites.
SOURCE: OGAC, 2005a, 2006a, 2007.
sites and laboratories that can provide the needed support (see Table 5-1). In addition, PEPFAR has provided funding and technical assistance to strengthen laboratory infrastructure and national procurement and supply chain systems.
REVIEW OF PROGRESS TO DATE
Support for National Programs to Follow theWorld Health Organization’s Guidelines
Nearly all of the focus countries have developed treatment targets and published plans for scaling up ART to meet those targets. While each focus country has a program tailored to its particular circumstances, all the programs are based on WHO’s recommendations for delivery of ART in resource-limited settings. PEPFAR has both supported the development of national treatment plans and endeavored to program its activities within the parameters of these national plans and the WHO guidelines. Although concerns have been expressed by several focus countries about the lack of consultation with local authorities during the initial development of PEPFAR treatment programs, and there has been widespread frustration with PEPFAR limits on the procurement of ARVs, PEPFAR’s support for ART appears to be generally consistent with national plans in the focus countries.
